In one tiny town, more than a dozen people were diagnosed with the rare neurodegenerative disease ALS. Why? I n March 2009, ...

The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary ...

Under current regulations, spouses can receive benefits only if the veteran lived with the disability for at least eight ...

CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...

The lifetime risk of developing ALS is about 1 in 300, with incidence increasing after age 50 and slightly higher rates in men than women. About 5-10% of cases are hereditary, while the remainder ...

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Transurban Group Ltd. (TRAUF – ...

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...

A patient with speech loss due to amyotrophic lateral sclerosis (ALS) has regained her ability to communicate her feelings, ...

“ALS is a complex illness ... analyzed with the Bayesian statistical method and reported as disease rate ratio (DRR) with DRR less than 1 indicating treatment benefit relative to placebo.

In this week’s InnovationRx newsletter, the worsening measles outbreak, a noninvasive brain-computer implant, replacing heart ...

UCLA Health researchers say study findings uncover Huntington's disease mechanisms and pave new ways to develop treatments.

A team of researchers from the Universitat Politècnica de València (UPV) and the French National Center for Scientific ...